"HitGen (688222.SH) today announced that it has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to UPPTHERA for further development. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment, success fee, license/milestone fee from UPPTHERA..."
top of page
Medical and Pharma Insider
Medical - Pharma - Biotech - Medical Devices - Healthcare - Telemedicine - Healthcare Technology - Healthcare IT
Your Source For Worldwide Business and Financial Opportunities
-
MedNews on financings, strategic relationships, products, services and technology, including launches
-
MedTalks videos featuring conversations with management of companies with business or financial objectives
bottom of page